clinical trial · NCT07636863
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
Bristol-Myers Squibb·—·completed·n = 200
CancerNivolumabSubcutaneous nivolumab combined with hyaluronidase
brief summary
This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.
started
Aug 21, 2025
primary completion
Dec 22, 2025
completion
Mar 27, 2026
last updated
Jun 9, 2026
official title
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig by Early Adopters
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol